Ex Parte Young et alDownload PDFPatent Trial and Appeal BoardFeb 15, 201913697591 (P.T.A.B. Feb. 15, 2019) Copy Citation UNITED STA TES p A TENT AND TRADEMARK OFFICE APPLICATION NO. FILING DATE 13/697,591 48003 7590 BGL/Cook - Chicago PO BOX 10395 CHICAGO, IL 60610 12/05/2012 02/15/2019 FIRST NAMED INVENTOR Peter Young UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www .uspto.gov ATTORNEY DOCKET NO. CONFIRMATION NO. 10703/306 (PA-6958-PCT/US 9765 EXAMINER TANNER, JOCELIN C ART UNIT PAPER NUMBER 3771 MAIL DATE DELIVERY MODE 02/15/2019 PAPER Please find below and/or attached an Office communication concerning this application or proceeding. The time period for reply, if any, is set in the attached communication. PTOL-90A (Rev. 04/07) UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Ex parte PETER YOUNG and PARVEZ MOONDI 1 Appeal2018-004775 Application 13/697,591 Technology Center 3700 Before STEFAN STAICOVICI, JAMES P. CALVE, and JEREMY M. PLENZLER, Administrative Patent Judges. CAL VE, Administrative Patent Judge. DECISION ON APPEAL STATEMENT OF THE CASE Appellants appeal under 35 U.S.C. § 134(a) from the Office Action finally rejecting claims 1 and 5-10. Claims 2--4 are cancelled and claims 11-20 are withdrawn. See Br. 19, 20 (Claims App.). We have jurisdiction under 35 U.S.C. § 6(b). We AFFIRM. 1 Cook Medical Technologies LLC is identified as the real party in interest. Br. 3. Appeal2018-004775 Application 13/697,591 CLAIMED SUBJECT MATTER Claim 1, the sole independent claim, is reproduced below. 1. A dilating device for providing access through body tissue to a body cavity for insertion of a tubular member therein, comprising: a pair of elongated members pivotally joined to each other along a length of each of said elongated members, each elongated member having a pivot point for joinder to the other elongated member, a proximal end accessible to an operator during use of said dilating device, and a distal end for insertion through said tissue, each distal end terminating at a substantially blunt distal tip, said respective distal ends movable between a closed position wherein said distal ends are at least substantially contiguous to each other, and an open position wherein said distal ends are separable for dilating said tissue, at least one of said elongated members having a channel extending through a length thereof, said channel having an entry opening, and having an exit opening distal of said entry opening along the length of said at least one elongated member, wherein said channel is configured to allow a wire to pass into the entry opening, through the channel, and out of the exit opening, wherein said distal tips of said distal ends of said elongated members are configured for blunt dissection of tissue of an intercostal space into a pleural cavity without causing injury to underlying structures including a heart, lung and liver, wherein said entry opening is proximal of said pivot point along said length, and said exit opening is distal of said pivot point along said length of said at least one elongated member and at said distal tip of said elongated member, and wherein said exit opening is disposed at a central portion of said distal tip of said elongated member. Br. 19 (Claims App.). 2 Appeal2018-004775 Application 13/697,591 REJECTIONS Claims 1 and 5-10 are rejected under 35 U.S.C. § I03(a) as being unpatentable over Uwaydah (EP O 792 621 Al, pub. Sept. 3, 1997) and Burbank (US 2003/0191391 Al, pub. Oct. 9, 2003). Claims 1 and 5-10 are rejected under 35 U.S.C. § I03(a) as being unpatentable over Levin (US 6,001,120, iss. Dec. 14, 1999), Uwaydah, and Burbank. Claims 1 and 5-10 are rejected under 35 U.S.C. § I03(a) as being unpatentable over Bertolero (US 6,309,349 Bl, iss. Oct. 30, 2001), Uwaydah, and Burbank. ANALYSIS Claims 1 and 5-10 Unpatentable Over Uwaydah and Burbank Appellants argue claims 1 and 5-10 as a group. Br. 8-18. We select claim 1 as representative, with claims 5-10 standing or falling with claim 1. 37 C.F.R. § 4I.37(c)(l)(iv). The Examiner finds that Uwaydah teaches a dilating device with pivotally attached elongated members 6 that terminate at substantially blunt distal tips and include channels 1 Oa, 1 Ob that extend the length of the elongated members 6 between exit and entry openings 12a, 12b, 14a, 14b, but Uwaydah lacks exit openings at the distal tip of each elongated member as recited in claim 1. Final Act. 4--5. The Examiner relies on Burbank to teach a similar device with elongated members that include channels 120, 122 along their lengths and exit opening 126 located at a distal end of each member. Id. at 5. The Examiner reasons that it would have been obvious to a person of ordinary skill in the art to form the exit openings ofUwaydah at the distal tips, as taught by Burbank, to accurately guide the needle out of the elongated member. Id. 3 Appeal2018-004775 Application 13/697,591 The Examiner finds that Uwaydah disposes channels centrally through elongated members, and Burbank disposes channel exit openings at a distal tip of each elongated member so "by modifying the channels ofUwaydah to continue to extend to the distal tip, as taught by Burbank, the centrally extending channels ofUwaydah would include exit openings disposed at a central portion of the distal tip of each elongated member." Ans. 3. Appellants argue that neither reference teaches a dilating device with an exit opening disposed at a central portion of the distal tip of an elongated member as claimed. Br. 9. Appellants argue that Burbank positions a guide channel distal opening 126 at an outer edge of the end face 144 of the distal tip of the elongated members rather than at a central portion as claimed. Id. at 10. Appellants argue that modifying Burbank to locate its guide channel openings at the central portion of the end faces would render the device inoperative because it would place the distal opening in alignment with the uterine artery and block a suture from passing between the two end faces. Id. at 11-12, 13. Appellants also argue that Burbank, therefore, teaches away from the guide channel distal opening being at the central portion of the end face as claimed. Id. at 11. These arguments are not persuasive because they do not address the rejection of the Examiner as set forth in the Final Office Action and Answer. The Examiner is not modifying Burbank or its channels and distal openings. Rather, the Examiner is modifying the channels in the elongated members of the dilating device ofUwaydah based on teachings of Burbank to extend the channels so the distal openings are positioned on end faces of the elongated members, that is, are positioned on a central portion of the distal tip of each ofUwaydah's elongated members 6. Final Act. 5; Ans. 3. 4 Appeal2018-004775 Application 13/697,591 The Examiner does not propose to reposition the distal openings of the channels of Burbank's device to the central portions of the end faces of Burbank's device. Br. 11. The Examiner proposes to extend the centrally- located channels 1 Oa, 1 Ob that extend through each elongated member 6 of Uwaydah to the end faces, as Burbank teaches to do, "to provide means to accurately guide the needle out of the elongated member." Final Act. 5. The Examiner correctly finds that the channels in Uwaydah's elongated members are centrally-located in each member. See Uwaydah, Fig. 3. The Examiner correctly reasons that extending those central channels to the end faces of each elongated member would result in the distal openings of the channels being located in the central portions of each end face. Ans. 3-5 ("With this modification, the channels would continue to extend along the central portion of the elongated members, as taught by Uwaydah, and would terminate at the distal tip, as taught by Burbank."); Final Act. 14--15. The Examiner reasonably determines that extending the channels of Uwaydah's elongated members to the distal end faces, as taught by Burbank, would improve Uwaydah by providing a means to accurately guide a needle out of each elongated member. Id. at 5; Ans. 3. The Examiner's rationale is supported by the teachings of Burbank that a suture leader can be pushed through one guide channel 112 and out distal opening 126 in a face of the distal tip into distal port 130 of the guide channel 114 of the other elongated member. Burbank ,r 32. Moreover, Figure 1 ofUwaydah is exemplary of an exit port 14a of channel 1 Oa of elongated member 6a disposed in a central portion of distal tip clamping surface 8a in alignment with entrance port 12b of distal tip clamping surface 8b of elongated member 6b. See Uwaydah ,r 32 (disclosing that Figs. 1-3 illustrate an embodiment of the apparatus). 5 Appeal2018-004775 Application 13/697,591 Finally, Appellants argue that the Declaration of Peter Young, M.D. ("the Young Declaration") provides evidence of praise by others for the claimed device, and the Examiner did not consider this evidence in reaching the obviousness determination. Br. 13. Appellants argue that this evidence, which includes an award of Highly Commended Runner-Up, weighs against a determination that claim 1 is obvious. Id. at 14. Appellants argue that the Association of Anaesthetists of Great Britain and Ireland (AAGBI) scored their invention so highly "due to its innovative and original design of the dissecting forceps incorporating a channel for a guide wire." Id. (quoting letter of Dr. Bernard Liban on behalf of the AAGBI with emphasis added). In response, the Examiner finds that a nexus is lacking between the evidence of praise by others and the claimed device. Ans. 5. In particular, the Examiner finds that the secondary evidence of praise by others is not coextensive with the claims at issue. Id. We agree. "For objective evidence of secondary considerations to be accorded substantial weight, its proponent must establish a nexus between the evidence and the merits of the claimed invention." In re Kao, 639 F.3d 1057, 1068 (Fed. Cir. 2011) ( citation omitted). If a secondary consideration results from something other than what is claimed and novel in the claim, there is no nexus to the merits of the claimed invention. Id.; see also Takai Corp. v. Easton Enters., Inc., 632 F.3d 1358, 1369 (Fed. Cir. 2011) ("If commercial success is due to an element in the prior art, no nexus exists."); Ormco Corp. v. Align Tech., Inc., 463 F.3d 1299, 1312 (Fed. Cir. 2006) ("[I]f the feature that creates the commercial success was known in the prior art, the success is not pertinent."). 6 Appeal2018-004775 Application 13/697,591 Here, the alleged "novel" feature of the claimed device is an exit opening "disposed at a central portion of said distal tip of said elongated member." However, the industry praise relates to channels in the elongated members of the forceps. Dr. Young cites Dr. Liban's letter as evidence. Young Deel. ,r 29. Dr. Li ban praised "the innovative and original design of the dissecting forceps incorporating a channel for a guide wire." Id. at Ex. 4. Appellants' application to the AAGBI described their invention as "specially designed forceps with integrated channel." Id. at Ex. 3. Dr. Young declared that industry praise is for "at least one of said elongated members ... having a channel extending through the length thereof, said channel having an entry opening, and having an exit opening distal of said entry opening." Id. ,r 31. Uwaydah and Burbank disclose such channels in elongated members of forceps. Thus, no nexus has been shown between the industry praise and the merits of the claimed invention, i.e., an exit opening disposed at a central portion of the distal tip of the elongated member. See Bosch Auto. Serv. Solutions, LLC v. Mata!, 878 F.3d 1027, 1038 (Fed. Cir. 2017) (holding that patentee's evidence did not establish that the tools receiving awards from an industry magazine embodied the claimed subject matter); Asyst Techs., Inc. v. Emtrak, Inc., 544 F.3d 1310, 1316 (Fed. Cir. 2008) (holding that evidence of long-felt need and industry praise were not attributable to the inventive feature, i.e., to the substitution of a multiplexer for a bus, which was the only material difference between the prior art and the patented invention). In addition, Figure 1 ofUwaydah discloses this feature. See In re Aslanian, 590 F.2d 911, 914 (CCPA 1979) (holding that drawings in a utility patent can be cited against claims of a utility patent application including features in the drawing that are unexplained in the specification of the reference). 7 Appeal2018-004775 Application 13/697,591 Even if a nexus existed between the industry praise and the claimed invention, the evidence would not overcome the strong case of obviousness where the prior art discloses every feature of the claimed dilator. Rothman v. Target Corp., 556 F.3d 1310, 1322 (Fed. Cir. 2009) (holding that a strong obviousness showing may stand even in the face of considerable secondary considerations evidence); see also Wyers v. Master Lock Co., 616 F.3d 1231, 1246 (Fed. Cir. 2010) ("secondary considerations ofnonobviousness .. . simply cannot overcome a strong prima facie case of obviousness .... where the inventions represented no more than 'the predictable use of prior art elements according to their established functions,' KSR, 550 U.S. at 417 ... , the secondary considerations are inadequate to establish nonobviousness as a matter of law."); Asyst Techs., 544 F.3d at 1316 (holding that the secondary consideration evidence did not overcome the strong case of obviousness in the substitution of a multiplexer, a known alternative to Hesser's bus that operates in a well-known manner); Agrizap, Inc. v. Woodstream Corp., 520 F.3d 1337, 1344 (Fed. Cir. 2008) (holding that the objective evidence of nonobviousness cannot overcome a strong prima facie case of obviousness). Thus, we sustain the rejection of claims 1 and 5-10. Claims 1 and 5-10 Unpatentable Over Levin, Uwaydah, and Burbank The Examiner relies on Levin to teach a dilating device and Uwaydah and Burbank to teach channels extending through the elongated members to exit openings as for the previous rejection. Final Act. 6-8. Appellants argue that Levin does not disclose a channel extending through elongated members or an exit opening at a central portion of a distal tip of the elongated member and therefore Levin does not cure the deficiencies ofUwaydah and Burbank in this regard for claim 1. Br. 16. 8 Appeal2018-004775 Application 13/697,591 Because we sustain the rejection of claim 1 as unpatentable over Uwaydah and Burbank, there is no such deficiency for Levin to remedy. Thus, we also sustain the rejection of claims 1 and 5-10 as unpatentable over Levin, Uwaydah, and Burbank. Claims 1 and 5-10 Unpatentable Over Bertolero, Uwaydah, and Burbank The Examiner relies on Bertolero to teach a dilating device and Uwaydah and Burbank to teach channels extending through the elongated members to exit openings. Final Act. 10-12. Appellants argue that Bertolero does not disclose a channel extending through elongated members or an exit opening at a central portion of a distal tip of the elongated member and therefore Bertolero does not cure the deficiencies ofUwaydah and Burbank in this regard for claim 1. Br. 16. Because we sustain the rejection of claim 1 as unpatentable over Uwaydah and Burbank, there is no such deficiency for Bertolero to remedy. Thus, we also sustain the rejection of claims 1 and 5-10 as unpatentable over Bertolero, Uwaydah, and Burbank. DECISION We affirm the prior art rejections of claims 1 and 5-10. No time period for taking any subsequent action in connection with this appeal may be extended under 37 C.F.R. § 1.136(a)(l )(iv). AFFIRMED 9 Copy with citationCopy as parenthetical citation